These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3088 related articles for article (PubMed ID: 6683178)

  • 1. Antitumor activity in mice of 4'-deoxydoxorubicin in comparison with doxorubicin.
    Casazza AM; Savi G; Pratesi G; Di Marco A
    Eur J Cancer Clin Oncol; 1983 Mar; 19(3):411-8. PubMed ID: 6683178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin.
    Barbieri B; Giuliani FC; Bordoni T; Casazza AM; Geroni C; Bellini O; Suarato A; Gioia B; Penco S; Arcamone F
    Cancer Res; 1987 Aug; 47(15):4001-6. PubMed ID: 3607745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antineoplastic activity of 4'-deoxydoxorubicin in murine solid tumors.
    Marmonti L; Jin XQ; Filippeschi S; Spreafico F
    Anticancer Res; 1984; 4(6):425-9. PubMed ID: 6517535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.
    Goldin A; Venditti JM; Geran R
    Invest New Drugs; 1985; 3(1):3-21. PubMed ID: 3886588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor spectrum of a new anthracycline, (2"R)-4'-O-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice.
    Hisamatsu T; Suzuki K; Sakakibara S; Komuro K; Nagasawa M; Takeuchi T; Umezawa H
    Jpn J Cancer Res; 1985 Oct; 76(10):1008-20. PubMed ID: 3935619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines.
    Penco S; Casazza AM; Franchi G; Barbieri B; Bellini O; Podestà A; Savi G; Pratesi G; Geroni C; Di Marco A; Arcamone F
    Cancer Treat Rep; 1983; 67(7-8):665-73. PubMed ID: 6575865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
    Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
    Corbett TH; Griswold DP; Mayo JG; Laster WR; Schabel FM
    Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaches to combination chemotherapy in rat, mouse, and hamster tumors.
    Griswold DP; Dykes DJ; Kelley CA; Roberts BJ; Dominick CA
    Cancer Chemother Rep 2; 1974 Mar; 4(1):99-108. PubMed ID: 4524043
    [No Abstract]   [Full Text] [Related]  

  • 10. New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse.
    Giuliani FC; Kaplan NO
    Cancer Res; 1980 Dec; 40(12):4682-7. PubMed ID: 7438099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.
    Ganzina F
    Cancer Treat Rev; 1983 Mar; 10(1):1-22. PubMed ID: 6342772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial with 4'-deoxydoxorubicin (esorubicin).
    Rozencweig M; Crespeigne N; Kenis Y
    Invest New Drugs; 1983; 1(4):309-13. PubMed ID: 6678877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells.
    Capranico G; De Isabella P; Penco S; Tinelli S; Zunino F
    Cancer Res; 1989 Apr; 49(8):2022-7. PubMed ID: 2702645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental evaluation of anthracycline analogs.
    Casazza AM
    Cancer Treat Rep; 1979 May; 63(5):835-44. PubMed ID: 455325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
    Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
    Bissery MC; Guénard D; Guéritte-Voegelein F; Lavelle F
    Cancer Res; 1991 Sep; 51(18):4845-52. PubMed ID: 1680023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
    Jones B; Komarnitsky P; Miller GT; Amedio J; Wallner BP
    Anticancer Drugs; 2012 Feb; 23(2):173-84. PubMed ID: 22027537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 155.